[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
Jan 9, 2012

Balancing Transparency and UncertaintyComment on “Potential Safety Signals and Their Significance”

Author Affiliations

Author Affiliations: Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.

Arch Intern Med. 2012;172(1):74-75. doi:10.1001/archinternmed.2011.546

For over 40 years, analysis of spontaneous adverse event reporting has been the cornerstone of the drug safety surveillance system of the Food and Drug Administration (FDA). This system, which relies on observations made at the point of care, is used to identify adverse drug reactions (ADRs) that were not detected during clinical trials but emerge after a product is marketed and used in a wider population. Results of this surveillance system have been used for many regulatory actions.1

First Page Preview View Large
First page PDF preview
First page PDF preview